Finerenone blocks mineralocorticoid receptors. Excessive activation of these receptors in chronic kidney disease and type 2 diabetes contributes to inflammation and fibrosis in kidney and heart tissue. Blocking these receptors helps reduce pathological processes associated with organ damage.
It may be prescribed for:
Research:
Finerenone requires monitoring of serum potassium and kidney function. Hyperkalemia is one of the most important safety concerns, so dosing is adjusted according to estimated glomerular filtration rate and serum potassium levels.
Kerendia is indicated in adults with chronic kidney disease associated with type 2 diabetes to reduce the risk of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure.
It is also indicated in certain adults with heart failure and left ventricular ejection fraction ≥40% to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.
Finerenone works through selective blockade of mineralocorticoid receptors, reducing their pathological activation in kidney and cardiac tissue.
Kerendia is taken orally once daily, with or without food. The starting dose is determined by estimated glomerular filtration rate and serum potassium; for patients with an eGFR ≥60 mL/min/1.73 m², the recommended starting dose is 20 mg once daily, while patients with an eGFR of 25 to less than 60 mL/min/1.73 m² generally start at 10 mg. Serum potassium and kidney function should be assessed before treatment and approximately 4 weeks after starting or changing the dose.
Side Effects
The most clinically important adverse reaction is increased serum potassium, making regular laboratory monitoring particularly important.
